Gilead Sciences is all set for its next big launch. On Wednesday, a day after the company reported a disappointing hepatitis C sales outlook, the drugmaker got a needed boost with the FDA’s approvalfor HIV combo drug Biktarvy.
Gilead’s Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline strikes back
Leave a Comment